Methylene blue, Mycophenolic acid, Posaconazole, and Niclosamide inhibit SARS-CoV-2 Omicron variant BA.1 infection of human airway epithelial organoids
Sublineages of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) Omicron variants continue to amass mutations in the spike (S) glycoprotein, which leads to immune evasion and rapid spread of the virus across the human population. Here we demonstrate the susceptibility of the Omicron varia...
Main Authors: | Romain Volle, Luca Murer, Anthony Petkidis, Vardan Andriasyan, Alessandro Savi, Cornelia Bircher, Nicole Meili, Lucy Fischer, Daniela Policarpo Sequeira, Daniela Katharina Mark, Alfonso Gomez-Gonzalez, Urs F. Greber |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-01-01
|
Series: | Current Research in Microbial Sciences |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666517422000554 |
Similar Items
-
Niclosamide (NA) overcomes cisplatin resistance in human ovarian cancer
by: Linjuan Huang, et al.
Published: (2023-07-01) -
Pharmacokinetic considerations for enhancing drug repurposing opportunities of anthelmintics: Niclosamide as a case study
by: Jeong In Seo, et al.
Published: (2024-04-01) -
Mycophenolate suppresses inflammation by inhibiting prostaglandin synthases: a study of molecular and experimental drug repurposing
by: Fahad Al-Hizab, et al.
Published: (2021-04-01) -
Combination of niclosamide and current therapies to overcome resistance for cancer: New frontiers for an old drug
by: Junyi Ren, et al.
Published: (2022-11-01) -
In Vitro Evaluation and Mitigation of Niclosamide’s Liabilities as a COVID-19 Treatment
by: Jesse W. Wotring, et al.
Published: (2022-08-01)